Teva prices $3.2 billion and €1.5 billion in senior notes, partly to redeem older debt
On September 16, 2026, Teva's subsidiaries issued €1.5 billion and $3.2 billion of senior unsecured notes due 2032 to 2037, guaranteed by Teva Pharmaceutical Industries. Teva plans to use the proceeds to fund conditional redemptions of several existing notes, pay related fees, and for general corporate purposes. The filing shows a refinancing of existing debt rather than a stated change in operations or results.
Key points
- Euro notes: €1.0 billion of 4.250% notes due March 16, 2033, and €500 million of 4.625% notes due September 16, 2036
- USD notes: $1.2 billion of 5.250% notes due January 16, 2032; $1.0 billion of 5.500% notes due January 16, 2034; and $1.0 billion of 5.750% notes due January 16, 2037
- Conditional redemptions include up to $450 million of 4.750% notes due 2027 and up to €1.15 billion of 4.375% notes due 2030, reduced from up to €1.25 billion
- Teva may redeem notes, or issue further redemption notices, at its sole discretion and is under no obligation to do so
The filing
Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.